Parabilis Medicines (formerly Fog Pharmaceuticals), a clinical-stage biopharmaceutical company committed to creating ...

Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company ...

Jordan’s renewed crackdown on the Muslim Brotherhood reflects growing regime insecurity and its deepening collaboration with Israel.

How alterations in cell metabolism translate into specific developmental gene programs remains a major question. This study ...

DelveInsight's "IBRANCE Market Size, Forecast, and Market Insight Report" highlights the details around IBRANCE, a CDK4/6 inhibitor. The report provides product descriptions, patent details, and ...

Peter Gratton, M.A.P.P., Ph.D., is a New Orleans-based editor and professor with over 20 years of experience in investing, risk management, and public policy. Peter began covering markets at ...

A program cochair said the agenda was designed to get attendees "out of their comfort zone." The Amercian Association for ...

AstraZeneca has started work with tech companies Tempus and Pathos AI on a project that aims to generate a wide-ranging and ...

Luveltamab tazevibulin demonstrated activity in an ongoing phase 2/3 trial of patients with FRα-positive, platinum-resistant ovarian cancer.

Experts developed consensus recommendations through the modified Delphi process for metastatic prostate cancer management ...